1. Home
  2. Directory
  3. New York
  4. New York New York
  5. Psychiatry Neurology
  6. NPI Profile
  7. Prescriptions 1578069746

DR. MUSTAFA ABBAS TAQUEE MD
Prescription History 1578069746
Psychiatry & Neurology - Psychiatry in New York, NY

NPI Status: Active since April 04, 2018

Contact Information

109 W 27TH ST
NEW YORK, NY
ZIP 10001
Phone: (917) 634-5311

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. MUSTAFA ABBAS TAQUEE MD, an active Psychiatry specialist practicing in New York, NY. Our medical registry currently tracks 2 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 24 documented patient claims. Among these therapy options, the most frequently utilized medication is Lamotrigine, which accounts for 13 claims alone.

Medication Index

C
L
No matching medications currently found on file.

Clonazepam

Generic Formulation: ClonazepamSpecialty: Psychiatry
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 255
NY State Average Benchmarks
Peer Average Claims51.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,511
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 78.4% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $78.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.15

State Avg Cost Per Claim

$10.30

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.

Therapeutic Applications

Clonazepam is used to prevent and control seizures. This medication is known as an anticonvulsant or antiepileptic drug. It is also used to treat panic attacks. Clonazepam works by calming your brain and nerves. It belongs to a class of drugs called benzodiazepines.

Lamotrigine

Generic Formulation: LamotrigineSpecialty: Psychiatry
Provider Metrics Summary
Total Claims 13
30-Day Fills 15.0
Days Supply 433
NY State Average Benchmarks
Peer Average Claims45.0
Peer Average 30-Day Fills63.0
Peer Average Days Supply1,843
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 71.1% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $273.41 across this reporting matrix range.

Provider Avg Cost Per Claim

$21.03

State Avg Cost Per Claim

$16.24

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A phenyltriazine compound, sodium and calcium channel blocker that is used for the treatment of SEIZURES and BIPOLAR DISORDER.

Therapeutic Applications

Lamotrigine is used alone or with other medications to prevent and control seizures. It may also be used to help prevent the extreme mood swings of bipolar disorder in adults. Lamotrigine is known as an anticonvulsant or antiepileptic drug. It is thought to work by restoring the balance of certain natural substances in the brain. This drug is not approved for use in children younger than 2 years due to an increased risk of side effects (such as infections).

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. MUSTAFA ABBAS TAQUEE MD provides transparency into local medical care patterns within New York, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Psychiatry** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.